CellMosaic, Inc.

Excited to share CellMosaic’s latest product launch—fluorescent dye-based product lines featuring innovative small molecule and protein dye conjugates. These high-performance tools are designed to support cutting-edge research in drug delivery, flow cytometry, and more. Proud of the team for making this happen! ?? Check it out below ?? #bioconjugation #lifesciences #fluorescentdyes #researchtools #CellMosaic

?? New Product Launch Alert! CellMosaic? is proud to unveil our newest fluorescent dye-based product line—designed to support scientists in advancing discovery across diverse applications. ?? Now Available: ? Small Molecule Dye Conjugates – NIR dye-polysucrose-400 for permeability studies, cell tracking & more ? Protein Dye Conjugates – R-Phycoerythrin (PE)-Streptavidin conjugates for high-sensitivity biotin detection in flow cytometry, ELISAs, and microarrays ? Key Highlights for Protein Dye Conjugates: ? High-purity (≥99%) lyophilized reagents ? Stable, water-soluble conjugates ? Multiple labeling options for assay flexibility Whether you're tracking cells or detecting biotin with maximum sensitivity, CellMosaic's latest line delivers ready-to-use, high-performance tools for your lab. ?? Read the full announcement and explore all five new conjugates: ?? https://lnkd.in/eJHydFKp #fluorescentdyes #bioconjugation #flowcytometry #ELISA #lifesciences #researchtools #cellmosaic

?? New ADC and PDC PerKit? Products! We’re excited to introduce our latest PerKit? ADC additions, now featuring Exatecan and PBD dimer! Plus, we’ve added SN38 with a clinically validated releasable VC-PAB linker to this batch. These new offerings expand our high-quality, ready-to-use bioconjugation solutions, helping researchers accelerate their ADC and PDC development. ?? Learn more in our latest blog: https://lnkd.in/ejG9ADUn #Bioconjugation #ADC #PDC #PerKit #DrugDiscovery #CellMosaic

For anyone interested in antibody production or preparing conjugates for immunization or diagnostic applications, we’ve got you covered! Check out our new maleimide-activated BSA and KLH products, designed to streamline your conjugation process.

New Product Release CellMosaic is proud to introduce three new maleimide-activated protein carrier products for immunization and diagnostic applications. Designed for conjugation with cysteine (Cys) peptides, as well as small molecules and biopolymers containing free thiol groups, these products provide flexibility to meet diverse research needs. Maleimide Activated BSA ML: 10-20 maleimide groups (2 mg & 6 mg) Maleimide Activated BSA LL: 2-8 maleimide groups (2 mg & 6 mg) Maleimide Activated KLH ML: 10-30 maleimide groups (2 mg & 6 mg) For more information, please check our blog here: https://lnkd.in/eGKpNfyc

?? ONLY HOURS LEFT TO INVEST IN THE FUTURE OF MEDICINE While others promise breakthroughs, we're delivering results: ?? $6.9M+ revenue ?? 500+ research partners ?? 12 patents & growing Our precision medicine isn't just a vision—it's already generating revenue. But time's running out to be part of it. Invest for as little as $250.?? https://bit.ly/4gZRufu This Reg CF offering is made available through StartEngine Primary LLC, member FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. #BioTech #MedTech #StartEngine #ADC #RegCF

?? FINAL DAYS TO INVEST IN THE FUTURE OF MEDICINE. Think of it as GPS for powerful drugs—we help life-saving treatments find diseased cells while avoiding healthy ones. Not just an idea: ?? Used by 500+ research teams worldwide ?? Trusted by Mass General Brigham ?? Expanding from cancer to addiction treatment We invite you to join our investor community before our StartEngine offering ends.?? https://bit.ly/4gZRufu This Reg CF offering is made available through StartEngine Primary LLC, member FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. #BioTech #MedTech #StartEngine #ADC #RegCF

Every 7 minutes, someone in America loses their life to an opioid overdose. At CellMosaic, we're proud to support researchers working to change this statistic. We recently hosted Dr. Kathryn Frietze from the University of New Mexico to discuss her lab's innovative approach: a vaccine that could prevent opioid overdoses. Our proprietary chemistry enables their research team to create precise molecular connections that other companies couldn't achieve. Read our latest blog post to learn how this collaboration showcases the broader potential of CellMosaic's technology in advancing precision medicine: https://bit.ly/3EnnVpP This Reg CF offering is made available through StartEngine Primary LLC, member FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. #BioTech #MedTech #StartEngine #ADC #RegCF

Behind every cancer breakthrough is countless hours of precise lab work. Here's Annie in our Massachusetts facility, preparing specialized compounds that help make treatments more targeted and less toxic. Invest on StartEngine today.?? https://bit.ly/4gZRufu This Reg CF offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. #BioTechnology #LabScience #Biotechnology #AntibodyEngineering #DrugDevelopment #WomenInSTEM #Innovation #Research #PrecisionMedicine #Science

Interested in joining our mission to transform drug delivery science? Check out our latest 120-second video on YouTube: https://lnkd.in/emWB4vsx. The video highlights CellMosaic's mission, cutting-edge technologies, customer success stories, recognitions, and track record as of January 2025. ?? Stay Connected: Follow us on LinkedIn for updates on new videos featuring our ADC products, bioconjugation tutoring, and innovative kits. Note: CellMosaic is currently accepting investments through StartEngine. Our investment offering closes on Jan 30. Learn more at https://lnkd.in/eTcgi3wT This Reg CF offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.